Royce & Associates LP Has $7.67 Million Stock Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Royce & Associates LP lifted its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 10.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 986,073 shares of the medical instruments supplier’s stock after purchasing an additional 96,138 shares during the quarter. Royce & Associates LP’s holdings in AngioDynamics were worth $7,672,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of ANGO. Quarry LP lifted its stake in AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 2,594 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of AngioDynamics by 9.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier’s stock valued at $199,000 after acquiring an additional 2,821 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in AngioDynamics by 44.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 4,780 shares during the period. CWM LLC grew its position in AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after purchasing an additional 8,832 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in AngioDynamics during the 3rd quarter valued at $86,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Stock Down 0.6 %

AngioDynamics stock opened at $6.81 on Monday. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $8.25. The stock has a market cap of $276.69 million, a P/E ratio of -1.12 and a beta of 0.67. The company’s fifty day simple moving average is $7.00 and its 200-day simple moving average is $6.77.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The company had revenue of $67.50 million for the quarter, compared to analyst estimates of $67.93 million. During the same period in the prior year, the firm posted ($0.12) EPS. The business’s revenue was down 14.2% compared to the same quarter last year. On average, equities research analysts expect that AngioDynamics, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Activity at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer bought 20,000 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was bought at an average cost of $6.03 per share, with a total value of $120,600.00. Following the completion of the transaction, the chief executive officer now directly owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. The trade was a 3.02 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have acquired 22,568 shares of company stock valued at $135,847. 5.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ANGO has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of AngioDynamics in a report on Friday, October 4th. Canaccord Genuity Group lowered their target price on AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.